IMR Press / FBL / Volume 14 / Issue 8 / DOI: 10.2741/3421

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Chemical genetic screening of KRAS-based synthetic lethal inhibitors for pancreatic cancer
Show Less
1 Department of Pharmacology and Toxicology, The University of Texas Medical Branch, 301 University Boulevard, Galveston, Texas 77555-1031,USA
2 Sealy Center for Cancer Cell Biology, The University of Texas Medical Branch, 301 University Boulevard, Galveston, Texas 77555-1031,USA
3 Laboratory of Chemical Biology, School of Life Science and Technology ,China Pharmaceutical University, 24 Tongjia Street, Nanjing, Jiangsu Province, 210009, People’s Republic of China

Academic Editor: Xiaodong Cheng

Front. Biosci. (Landmark Ed) 2009, 14(8), 2904–2910; https://doi.org/10.2741/3421
Published: 1 January 2009
(This article belongs to the Special Issue Cyclic nucleotide signaling and drug discovery)
Abstract

Pancreatic cancer is one of the deadliest diseases largely due to difficulty in early diagnosis and the lack of effective treatments. KRAS is mutated in more than 90% of pancreatic cancer patients, and oncogenic KRAS contributes to pancreatic cancer tumorigenesis and progression. In this report, using an oncogenic KRASV12-based pancreatic cancer cell model, we developed a chemical genetic screen to identify small chemical inhibitors that selectively target pancreatic cancer cells with gain-of-function KRAS mutation. After screening ~3,200 compounds, we identified one compound that showed selective synthetic lethality against the KRASV12 transformed human pancreatic ductal epithelial cell over its isogenic parental cell line. These selective KRASV12-synthetic lethal compounds may serve as leads for subsequent development of clinically-effective treatments for pancreatic cancer.

Share
Back to top